Your browser doesn't support javascript.
Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles.
Touizer, Emma; Alrubayyi, Aljawharah; Ford, Rosemarie; Hussain, Noshin; Gerber, Pehuén Pereyra; Shum, Hiu-Long; Rees-Spear, Chloe; Muir, Luke; Gea-Mallorquí, Ester; Kopycinski, Jakub; Jankovic, Dylan; Jeffery-Smith, Anna; Pinder, Christopher L; Fox, Thomas A; Williams, Ian; Mullender, Claire; Maan, Irfaan; Waters, Laura; Johnson, Margaret; Madge, Sara; Youle, Michael; Barber, Tristan J; Burns, Fiona; Kinloch, Sabine; Rowland-Jones, Sarah; Gilson, Richard; Matheson, Nicholas J; Morris, Emma; Peppa, Dimitra; McCoy, Laura E.
  • Touizer E; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Alrubayyi A; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Ford R; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hussain N; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Gerber PP; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Shum HL; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Rees-Spear C; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Muir L; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Gea-Mallorquí E; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Kopycinski J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Jankovic D; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Jeffery-Smith A; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Pinder CL; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Fox TA; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Williams I; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Mullender C; Mortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
  • Maan I; Institute for Global Health, University College London, London, UK.
  • Waters L; Mortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
  • Johnson M; Institute for Global Health, University College London, London, UK.
  • Madge S; Mortimer Market Centre, Department of HIV, Central and North West London NHS Trust, London, UK.
  • Youle M; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Barber TJ; The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, London, UK.
  • Burns F; The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, London, UK.
  • Kinloch S; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
  • Rowland-Jones S; The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, London, UK.
  • Gilson R; Institute for Global Health, University College London, London, UK.
  • Matheson NJ; The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, London, UK.
  • Morris E; Institute for Global Health, University College London, London, UK.
  • Peppa D; The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, London, UK.
  • McCoy LE; Institute for Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK.
iScience ; 26(1): 105862, 2023 Jan 20.
Article in English | MEDLINE | ID: covidwho-2165427
ABSTRACT
We assessed a cohort of people living with human immunodeficiency virus (PLWH) (n = 110) and HIV negative controls (n = 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all timepoints, PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls. We also observed a delayed development of neutralization in PLWH that was underpinned by a reduced frequency of spike-specific memory B cells (MBCs). Improved neutralization breadth was seen against the Omicron variant (BA.1) after the third vaccine dose in PLWH but lower nAb responses persisted and were associated with global MBC dysfunction. In contrast, SARS-CoV-2 vaccination induced robust T cell responses that cross-recognized variants in PLWH. Strikingly, individuals with low or absent neutralization had detectable functional T cell responses. These PLWH had reduced numbers of circulating T follicular helper cells and an enriched population of CXCR3+CD127+CD8+T cells after two doses of SARS-CoV-2 vaccination.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: IScience Year: 2023 Document Type: Article Affiliation country: J.isci.2022.105862

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: IScience Year: 2023 Document Type: Article Affiliation country: J.isci.2022.105862